The Food and Drug Administration inspected Lifeline of Ohio Organ Procurement, Inc. in Columbus on May 7, assessing its practices related to human cellular, tissue and gene therapies, according to data posted on the FDA’s website.
The inspection’s final report found that Lifeline of Ohio Organ Procurement, Inc. was not required to take any corrective action regarding its management operations.
The FDA conducts routine inspections nationwide to determine whether facilities and their products meet FDA-regulated standards designed to protect public health. The agency releases inspection outcomes to the public.
The agency’s website notes that the FDA is a federal organization tasked primarily with overseeing the safety and quality of human and animal drugs, biological products, medical devices and tobacco products.
Information in this article was obtained from the U.S. Food and Drug Administration. The source data can be found here.
